Editorial comment: Tenofovir nephrotoxicity-vigilance required

AIDS Reader

Volumn 15, Issue 7, 2005, Pages 362-363

  Fine, Derek M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ANTIRETROVIRUS AGENT; CIDOFOVIR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

AGING; DRUG MECHANISM; EARLY DIAGNOSIS; FANCONI RENOTUBULAR SYNDROME; GLUCOSURIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LOW DRUG DOSE; METABOLIC ACIDOSIS; NEPHROTOXICITY; NOTE; PROTEINURIA;

ADENINE; FANCONI SYNDROME; GLYCOSURIA; HIV INFECTIONS; HUMANS; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; PHOSPHONIC ACIDS; PROTEINURIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 22144450010     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (15)

1. Ross MJ, Klotman PE. Recent progress in HIV-associated nephroathy. J Am Soc Nephrol. 2002;13:2997-3004.
2. Lucas GM, Eustace JA, Sozio S, et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study. AIDS. 2004;18:541-546.
3. Selik RM, Byers RH Jr, Dworkin MS. Trends in diseases reported on US death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr. 2002;29:378-387.
4. Tanji N, Tanji K, Kambham N, et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001;32:734-740.
5. Cihlar T, Ho ES, Lin DC, Mulato AS. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20(4-7):641-648.
6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003;348:800-807.
7. ADHOC International Steering Committee. A randomized placebo-conrolled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med. 2002;3:229-238.
8. Rollot F, Nazal EM, Chauvelot-Moachon L, et al. Tenofovir-related Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome: the role of lopinavir-ritonavir-didanosine. Clin Infect Dis. 2003;37:e174-176.
9. Squires K, Pozniak AL, Pierone G Jr, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a randomized trial. Ann Intern Med. 2003;139(5 pt1):313-320.
10. Schooley RT, Ruane P, Myers RA, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS. 2002;16:1257-1263.
11. Quimby D, Brito MO. Fanconi syndrome associated with the use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Reader. 2005;15:357-364.
12. Harris M, Yip B, Zalunardo N, et al. Increases in creatine during therapy with tenofovir DF. Presented at the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, July 13-16, 2003; Paris Abstract 55.
13. Reynes J, Peyriere H, de Boever CM, Le Moing V. Renal tubular injury and severe hypophosphoremia (Fanconi syndrome) associated wit tenofovir therapy. Presented at the 10th Conference on Retroviruses and Opportunistic Infections, February 10-14, 2003. Boston. Abstract 717.
14. Peyriere H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Imune Defic Syndr. 2004;35: 269-273.
15. Gupta SK, Eustace JA, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patirents: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559-1585.